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Antiretroviral agents have led to dramatic advance-
ments in life expectancy and quality of life for peo-
ple living with HIV/AIDS. Despite this progress, lower- 
income countries are forced to use older, less expensive 
antiretrovirals such as stavudine, which are associated 
with a relatively high frequency of late toxic effects. 
Nevertheless, the older antiretrovirals are likely to re-
main the backbone of the national first-line highly ac-
tive antiretroviral therapy (HAART) regimen in South 
Africa for the foreseeable future due to cost con-
straints.1,2 One of the more common late toxic effects 
of older antiretrovirals is lipodystrophy syndrome (LD).
LD is an umbrella term referring to peripheral lipo- 
atrophy (LA), central lipohypertrophy (LH), and dys-
lipidaemia associated with insulin resistance.3,4 These 
may occur alone or in combination. Although LD was 
initially thought to be a syndrome of fat redistribution 
resulting in peripheral LA combined with central LH, 
preliminary data from the FRAM study in adults (Study 
of Fat Redistribution and Metabolic Change in HIV in-
fection)5 indicate that LH and LA are less closely linked 
than was previously presumed. Other authors have also 
noted that LH and LA often occur independently of one 
another.6 In addition, dyslipidaemia associated with 
HAART may occur in the absence of LA or LH.7 
LA results in disfigurement, particularly of the face (Figs 
1 - 6), which can lead to stigmatisation and even forced 
disclosure of HIV status. This disfigurement has a major 
impact on adherence, particularly in adolescents.3,6,7 In 
addition, the long-term health consequences of LD in 
HIV-infected children, who require lifetime antiretrovi-
rals, are considerable: the most important consequence 
arises from dyslipidaemia and insulin resistance, which 
are known to significantly accelerate lifetime risk for 
cardiovascular disease in HIV-infected adults with LD.8 
It is unclear whether transient drug-induced dyslipi-
daemia in childhood increases the lifetime risk of car-
diovascular disease in children.9,10 Nonetheless, these 
negative health outcomes are of concern given that 
the prevalence of HAART-related LD in resource-lim-
ited settings may be as high as 47% after 2 years of 
therapy.6 
The mechanisms of LD have not yet been firmly estab-
lished. The mechanism of LA is related to mitochondrial 
damage, particularly in adipocytes.11 HAART-related ap-
optosis of adipocytes and suppression of pre-adipocyte 
differentiation have been described in protease inhibi-
tor (PI)-induced LA.12 A similar mechanism may occur 
in nucleoside reverse transcriptase inhibitor (NRTI)- 
induced LD, since it is known that NRTIs such as stavu-
dine can damage adipocyte mitochondria11 and cause 
a reduction in functioning mitochondria in adults.13 
Other chronic toxic effects such as lactic acidosis and 
peripheral neuropathy have also been associated with 
mitochondrial dysfunction.14,15 It has been suggested 
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that unknown agents released from damaged mito-
chondria in adipocytes may directly trigger apoptosis 
which leads to subcutaneous fat loss. Quantification of 
mitochondrial DNA in peripheral leucocytes may be an 
early warning sign of impending LD in patients exposed 
to antiretrovirals.16,17  Circulating growth hormone (GH) 
levels are significantly reduced in patients with LA/LH, 
and this is likely to aggravate the abnormal fat distri-
bution.18
HAART-related dyslipidaemia is thought to be mediated 
by a different, though related, mechanism: PI-induced 
alterations in adipokines and pro-inflammatory cy-
tokines cause an increased production of triglycerides 
and cholesterol in hepatocytes, while simultaneously 
inhibiting glucose uptake in peripheral adipocytes.19 
The risk of developing LD is strongly related to the dos-
age and duration of exposure to antiretroviral agents. 
The thymidine NRTIs (zidovudine and stavudine) and 
didanosine have been linked to LA/LH.20,21 In compari-
son, abacavir, tenofovir, and lamivudine have minimal 
or no LA/LH-causing effect.22 Non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) are considered a less 
potent cause of LA.7 Although efavirenz has been as-
sociated with lipomastia in some children, this usu-
ally resolves spontaneously without withdrawal of efa-
virenz.23,24 PIs have been linked to dyslipidaemia,25 and 
less strongly to LA/LH.21,26 
Stavudine, in particular, has been found to be a potent 
cause of LA in children when taken in the standard pae-
diatric dose of 1 mg/kg/dose twice daily.3,7,27,28 Owing to 
the long-term toxicity of this dose, stavudine is now 
rarely used in the developed world. A review by Hill 
et al.29 has recently led the World Health Organization 
(WHO) to recommend a reduction in the standardised 
dose of stavudine for adults weighing over 60 kg from 
40 mg to 30 mg twice daily,30 since it has been shown 
that a reduced dose results in a markedly lower risk of 
LD, while maintaining excellent antiviral efficacy.31,32 
The recommended dose of stavudine for children, how-
ever, has not yet been reduced. Since the dose of stavu-
dine is a major risk factor for the development of LD,33 
it would be reasonable to expect that the incidence of 
LD will fall when a lower dose is employed. The cur-
rent standard paediatric dose of stavudine (1 mg/kg/
dose twice daily) was extrapolated from the pharma-
cokinetic parameters of the adult dose of 40 mg twice 
daily, using data from a few small but well-controlled 
paediatric pharmacokinetic studies34-36 which showed 
that an oral dose of 1 mg/kg/dose twice daily in chil-
dren under 12 years results in plasma exposure similar 
to that of adults taking 40 mg twice daily, and that 
an oral dose of 0.5 mg/kg/dose twice daily in children 
results in plasma exposure similar to that of adults tak-
ing 20 mg twice daily.  
Particular mitochondrial DNA sub-groups (haplo-
groups) have been associated with a vulnerability to 
developing LA after exposure to HAART.37 A recent 
study showed that Caucasian American men on HAART 
who have the H mitochondrial haplogroup were at 
significantly increased risk of LA.37 In addition, certain 
mitochondrial DNA mutations may make an individual 
more vulnerable to developing LD when exposed to 
antiretroviral agents. This may occur because varia-
tions of mitochondrial DNA in adipocytes may reduce 
the efficiency of energy production or lead to increased 
oxygen free-radical production, resulting in a reduced 
mitochondrial reserve and an increased vulnerability to 
apoptosis when exposed to mitochondrial toxins such 
as antiretrovirals. 
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Significance of lipodystrophy syndrome
•    Lipodystrophy syndrome (LD) is common in HIV-
infected children, particularly in those taking 
didanosine, stavudine or zidovudine. 
•    Lipo-atrophy (LA) (a component of LD) causes 
major stigmatisation and interferes with adher-
ence.
•    LD may have significant long-term health conse-
quences, particularly cardiovascular. 
•    LA is largely permanent, so the focus remains on 
early detection and arresting progression. 
What to look out for
•    Look for a lean, muscular appearance of face and 
limbs with prominent limb veins due to loss of 
subcutaneous fat tissue. 
•    Compare the child’s tricep and bicep skin-fold 
thickness with your own as a rough guide.
•    Shrinking buttocks with or without an enlarging 
abdomen may be monitored using a waist-to-
hip ratio (WHR).
•    Children on HAART should have their blood lipids 
measured routinely every year.
What to do
Where subcutaneous LA or lipohypertrophy is di-
agnosed:
•    The most likely offending NRTI should be switched 
to abacavir (or tenofovir in adults).
Where dyslipidaemia is predominant:
•    A dietician review is helpful.
•    Consider switching to a PI-sparing regimen or 
to atazanavir.
•   Look for insulin resistance. 
•    Statins and metformin are only used in extreme 
cases.   
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A complex set of diagnostic criteria for the diagnosis of 
LD has been developed for adults by Carr et al.38 Equi-
valent diagnostic criteria for children have not been 
formally defined. Most clinicians employ a combination 
of objective anthropometric and biochemical measure-
ments and a subjective assessment in order to diagnose 
LD in children.6,7,33,39,40 Physical signs in children are 
due to loss of subcutaneous fat in limbs, buttocks and 
face, with or without accumulation of intra-abdomi-
nal visceral fat. Loss of limb fat results in prominent 
limb veins and a well-defined, muscular appearance of 
limbs in the presence of a normal or enlarged abdo-
men. Reduced skin-fold thickness (SFT) may be subjec-
tively assessed by comparing it with one’s own SFT as 
a rough guide. 
Loss of buttock fat, with or without enlargement of 
the abdomen, results in a greatly increased waist-to-
hip ratio (WHR). Breast enlargement and buffalo hump 
may occur after puberty. Other useful anthropometric 
measurements include mid-upper arm circumference 
(MUAC) and waist circumference, from which the 
waist-to-MUAC ratio can be calculated. SFT measure-
ments may be used to calculate the torso-to-arm ratio 
(TAR) as follows: TAR = [subscapular + suprailiac SKF]/
[bicep + tricep SFT]. A TAR z-score of >2.0 has been 
used as a diagnostic criterion in some studies.39 
As HAART-related dyslipidaemia may occur independ-
ently of LA/LH,5-7 children on HAART should have their 
blood lipids measured routinely at least once a year. 
Facial fat loss is often subtle and difficult to detect 
unless severe. The facial muscles are not normally no-
ticeable because they are covered in fat. Loss of facial 
fat results in a lean, muscular appearance of the face 
with deep laugh-lines when smiling. An old photo-
graph may be helpful. Figs 1 and 2 show a child with 
mild LA of the face. Some recovery is seen 4 years after 
changing from a stavudine-containing regimen (Fig. 3). 
Fig. 4 shows a child with moderate facial LA. Figs 5 
and 6 show a child with severe facial LA. Her LA was 
already advanced when she was changed from a sta-
vudine-containing regimen 4 years previously, and is 
unlikely to improve. 
To date there are limited data comparing the sensi-
tivity and specificity of anthropometric and biochemi-
cal diagnostic criteria against a gold standard such as 
dual-energy X-ray absorptiometry or magnetic reso-
nance imaging to diagnose early LA/LH in HIV-infected 
children. Studies are underway to define a practical set 
of diagnostic criteria to detect early LD in children in 
resource-limited settings. Since at least 30% of pe-
ripheral fat must be lost before LA becomes visibly evi-
dent,41 it is hoped that some combination of anthropo-
metric and biochemical measures will have reasonable 
sensitivity and specificity to detect LA/LH in children 
before it causes noticeable disfigurement (S Innes et al. 
– unpublished data). This will be an important contri-
bution to paediatric HIV care in the developing world. 
Fig. 2. Mild LA of the face, side view.
Fig. 1. Mild LA of the face, front view.
DiaGnOSiS
Fig. 3. The same child as in Fig. 1. Some recovery is seen 4 
years after withdrawal of stavudine.
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Since the disfiguration caused by LD is largely perma-
nent, the focus of management is on early detection 
and arrest of progression. Once identified, the most 
likely offending drug is usually withdrawn in an at-
tempt to prevent progression, and is replaced by a 
less LD-inducing antiretroviral. Where dyslipidaemia is 
identified, diet and lifestyle modification are essential. 
If severe and persistent (total cholesterol >13 mmol/l 
or triglycerides >8.5 mmol/l),1 the PI may be switched 
to a PI-sparing agent or changed to atazanavir/ritona-
vir (ATV/r), which has less effect on blood lipids.21 The 
effect of statins in lowering triglycerides and choles-
terol is well established;42 however, statins are only 
licensed for use in children over 12 years of age. The 
potential interaction of statins with PIs must be borne 
in mind. Metformin has been shown to be effective for 
LD-related insulin resistance in adults43 and for obes-
ity-related insulin resistance in HIV-uninfected chil-
dren.44 However, metformin is rarely used in LD-related 
insulin resistance in children.  
When LA/LH is diagnosed, significant benefit in halting 
progression has been shown from switching the thymi-
dine NRTI to a non-thymidine agent such as abacavir.21 
Tenofovir is generally avoided in children because of 
renal toxicity and osteopenia. However, there may be a 
place for switching to tenofovir in older children.45 This 
switch typically arrests progression of LA/LH, and may 
result in a small degree of reversal if LA is caught early. 
Various authors have demonstrated that the more ad-
vanced the LA, the less likely it is to reverse when the 
offending drug is removed.46,47 Intradermal injections 
of a biodegradable filler such as poly-L-lactic acid 
(Sculptura) can ameliorate the aesthetic effect of fa-
cial LA in adults,48 but this treatment is not appropriate 
for children. In addition, the cost is significant and the 
effect is not permanent and injections may need to be 
repeated. Uridine (NucleomaxX) partially reverses the 
mitochondrial toxicity caused by thymidine NRTIs, and 
may have a small but beneficial effect on disfiguring LA. 
Uridine is not currently available in South Africa, and it 
has no effect on dyslipidaemia.49 Growth hormone-re-
leasing hormone analogues (GH-RH) are helpful in the 
treatment of LA/LH.50 The mechanism probably involves 
reversing the reduced GH levels that are consistently 
found in patients with LA/LH. Although the side-ef-
fect profile of GH-RH therapy is attractive, the cost is 
prohibitive. Future treatments may involve adipokines 
such as leptin, but these remain experimental.21  
Research into reducing the paediatric dose of stavu-
dine is urgently needed in order to minimise the risk 
of LD without compromising antiviral efficacy, since 
the number of at-risk HIV-infected children exposed 
to long-term stavudine therapy in South Africa is 
very large. In addition, non-thymidine NRTIs such as 
abacavir and tenofovir should be more widely avail-
able, particularly in the public sector. 
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Fig. 4. Moderate LA of the face, front view. Note the loss of 
the buccal fat pad, resulting in lean, muscular appearance of 
the face with deep laugh-lines.
Fig. 6. Severe LA of the face, side view.
Fig. 5. Severe LA of the face, front view. This patient’s LA was 
already advanced when she was changed from a stavudine-
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Further research is needed to isolate the particular 
mitochondrial mutations that make a child vulnerable 
to LD. This may help public sector clinicians to pre-
dict which children should avoid thymidine NRTIs and 
rather be started on a more expensive, less LD-inducing 
antiretroviral regimen. 
Finally, since effective treatment of LD is difficult and 
remains beyond the reach of resource-limited rural 
communities, early detection is paramount. It is es-
sential to define a simple set of diagnostic criteria to 
identify early LD in children that can be easily imple-
mented in resource-limited settings. This will allow the 
progression of LD to be halted before it causes notice-
able disfigurement and stigmatisation. Children should 
be switched from stavudine (or zidovudine) to abacavir 
(and adults to tenofovir or abacavir) at the slightest 
sign of LD. 
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